|
|
To amend sections 3711.12 and 3719.41 and to enact | 1 |
sections 3711.13 and 3711.30 of the Revised Code | 2 |
to require reports to the Department of Health | 3 |
regarding newborns diagnosed as opioid dependent, | 4 |
to update the chemical name for a type of | 5 |
controlled substance, and to specify procedures | 6 |
for granting variances or waivers of any | 7 |
requirement in the rules governing operation of | 8 |
maternity homes. | 9 |
Section 1. That sections 3711.12 and 3719.41 be amended and | 10 |
sections 3711.13 and 3711.30 of the Revised Code be enacted to | 11 |
read as follows: | 12 |
Sec. 3711.12. (A) The director of health shall adopt rules in | 13 |
accordance with Chapter 119. of the Revised Code as the director | 14 |
considers necessary to implement the requirements of this chapter | 15 |
for licensure and operation of maternity units, newborn care | 16 |
nurseries, and maternity homes. The rules shall include provisions | 17 |
for the following: | 18 |
(1) Licensure application forms and procedures; | 19 |
(2) Renewal procedures, including procedures that address the | 20 |
right of the director of health, at the director's sole | 21 |
discretion, to conduct an inspection prior to renewal of a | 22 |
license; | 23 |
(3) Initial license fees and license renewal fees; | 24 |
(4) Fees for inspections conducted by the director under | 25 |
section 3711.10 of the Revised Code; | 26 |
(5) Safety standards, quality-of-care standards, and | 27 |
quality-of-care data reporting requirements; | 28 |
(6) Reporting and auditing requirements; | 29 |
(7) Inspection criteria, procedures, and guidelines; | 30 |
(8) Application forms to be used and procedures to be | 31 |
followed in applying under section 3711.13 of the Revised Code for | 32 |
a variance or waiver of any of the requirements of the rules | 33 |
adopted under this section regarding the operation of a maternity | 34 |
home; | 35 |
(9) Any other rules necessary to implement this chapter. | 36 |
(B) When adopting rules under this section, the director | 37 |
shall give consideration to recommendations regarding obstetric | 38 |
and newborn care issued by the American college of obstetricians | 39 |
and gynecologists; American academy of pediatrics; American | 40 |
academy of family physicians; American society of | 41 |
anesthesiologists; American college of nurse-midwives; United | 42 |
States centers for disease control and prevention; association of | 43 |
women's health, obstetric and neonatal nurses; and association of | 44 |
perioperative registered nurses, or their successor organizations. | 45 |
The director shall also consider the recommendations of the | 46 |
maternity and newborn advisory council established in section | 47 |
3711.20 of the Revised Code. | 48 |
Sec. 3711.13. (A) A board of health may grant a variance | 49 |
from or waiver of any of the requirements established in rules | 50 |
adopted under section 3711.12 of the Revised Code regarding the | 51 |
operation of a maternity home. | 52 |
(B) Each maternity home seeking a variance or waiver shall | 53 |
file an application with the board of health of the city or | 54 |
general health district in which the maternity home is located. | 55 |
The application shall be made on the form and in accordance with | 56 |
the procedures specified in rules adopted under section 3711.12 of | 57 |
the Revised Code. | 58 |
(C) The board of health shall review all applications | 59 |
received. Not later than forty-five days after receiving an | 60 |
application, the board shall determine whether to grant the | 61 |
variance or waiver and shall notify the applicant in writing of | 62 |
the board's decision. | 63 |
(D) Both of the following apply to a board of health in | 64 |
determining whether to grant a variance or waiver: | 65 |
(1) A variance shall be granted to an applicant if the board | 66 |
determines that the intent of a requirement has been met by the | 67 |
applicant in an alternate manner. | 68 |
(2) A waiver shall be granted if the board determines that | 69 |
strict application of a requirement would cause an undue hardship | 70 |
to the applicant and that granting the waiver would not jeopardize | 71 |
the health and safety of any patient or resident. | 72 |
(E) If a board of health denies a variance or waiver | 73 |
requested by a maternity home, the home may appeal the denial by | 74 |
filing a notice of appeal with the director of health. The notice | 75 |
must be filed not later than thirty days after the board's denial | 76 |
of the request. | 77 |
Not later than forty-five days after the notice of appeal is | 78 |
filed, the director shall either affirm the board's denial or | 79 |
grant the variance or waiver. The director shall notify the board | 80 |
and the maternity home in writing of the director's action. | 81 |
(F) Notwithstanding any other provision of this section, the | 82 |
director may void the board's granting of a waiver or variance | 83 |
issued under this section. The director shall notify the board and | 84 |
the maternity home in writing of the director's action not later | 85 |
than forty-five days after the decision to void. | 86 |
Sec. 3711.30. (A) As used in this section, "opioid" means | 87 |
opium, opium derivatives, and synthetic opium substitutes. | 88 |
(B) Each maternity unit, newborn care nursery, and maternity | 89 |
home shall report to the department of health the number of | 90 |
newborns born to residents of this state in the unit, nursery, or | 91 |
home during the preceding calendar quarter that were diagnosed as | 92 |
opioid dependent at birth. The reports shall be submitted not | 93 |
later than thirty days after the end of each quarter and shall not | 94 |
include any patient-identifying information. | 95 |
(C) The department shall establish standards and procedures | 96 |
for reporting the information required by this section. The | 97 |
information reported under this section shall not be used for law | 98 |
enforcement purposes or disclosed to law enforcement authorities. | 99 |
(D) The department shall compile the information submitted | 100 |
under this section and make a summary of that information | 101 |
available to the public not later than ninety days after the end | 102 |
of each calendar year. | 103 |
Sec. 3719.41. Controlled substance schedules I, II, III, IV, | 104 |
and V are hereby established, which schedules include the | 105 |
following, subject to amendment pursuant to section 3719.43 or | 106 |
3719.44 of the Revised Code. | 107 |
108 | |
(A) Narcotics-opiates | 109 |
Any of the following opiates, including their isomers, | 110 |
esters, ethers, salts, and salts of isomers, esters, and ethers, | 111 |
unless specifically excepted under federal drug abuse control | 112 |
laws, whenever the existence of these isomers, esters, ethers, and | 113 |
salts is possible within the specific chemical designation: | 114 |
(1) Acetyl-alpha-methylfentanyl | 115 |
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); | 116 |
(2) Acetylmethadol; | 117 |
(3) Allylprodine; | 118 |
(4) Alphacetylmethadol (except levo-alphacetylmethadol, also | 119 |
known as levo-alpha-acetylmethadol, levomethadyl acetate, or | 120 |
LAAM); | 121 |
(5) Alphameprodine; | 122 |
(6) Alphamethadol; | 123 |
(7) Alpha-methylfentanyl | 124 |
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; | 125 |
1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine); | 126 |
(8) Alpha-methylthiofentanyl | 127 |
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- | 128 |
phenylpropanamide); | 129 |
(9) Benzethidine; | 130 |
(10) Betacetylmethadol; | 131 |
(11) Beta-hydroxyfentanyl | 132 |
(N-[1-(2-hydroxy-2-phenethyl-4-piperidinyl]-N- phenylpropanamide); | 133 |
(12) Beta-hydroxy-3-methylfentanyl (other name: | 134 |
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N- | 135 |
phenylpropanamide); | 136 |
(13) Betameprodine; | 137 |
(14) Betamethadol; | 138 |
(15) Betaprodine; | 139 |
(16) Clonitazene; | 140 |
(17) Dextromoramide; | 141 |
(18) Diampromide; | 142 |
(19) Diethylthiambutene; | 143 |
(20) Difenoxin; | 144 |
(21) Dimenoxadol; | 145 |
(22) Dimepheptanol; | 146 |
(23) Dimethylthiambutene; | 147 |
(24) Dioxaphetyl butyrate; | 148 |
(25) Dipipanone; | 149 |
(26) Ethylmethylthiambutene; | 150 |
(27) Etonitazene; | 151 |
(28) Etoxeridine; | 152 |
(29) Furethidine; | 153 |
(30) Hydroxypethidine; | 154 |
(31) Ketobemidone; | 155 |
(32) Levomoramide; | 156 |
(33) Levophenacylmorphan; | 157 |
(34) 3-methylfentanyl | 158 |
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N- phenylpropanamide); | 159 |
(35) 3-methylthiofentanyl | 160 |
(N-[3-methyl-1-[2-(thienyl)ethyl]-4-piperidinyl]-N- | 161 |
phenylpropanamide); | 162 |
(36) Morpheridine; | 163 |
(37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); | 164 |
(38) Noracymethadol; | 165 |
(39) Norlevorphanol; | 166 |
(40) Normethadone; | 167 |
(41) Norpipanone; | 168 |
(42) Para-fluorofentanyl | 169 |
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide; | 170 |
(43) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine; | 171 |
(44) Phenadoxone; | 172 |
(45) Phenampromide; | 173 |
(46) Phenomorphan; | 174 |
(47) Phenoperidine; | 175 |
(48) Piritramide; | 176 |
(49) Proheptazine; | 177 |
(50) Properidine; | 178 |
(51) Propiram; | 179 |
(52) Racemoramide; | 180 |
(53) Thiofentanyl | 181 |
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide; | 182 |
(54) Tilidine; | 183 |
(55) Trimeperidine. | 184 |
(B) Narcotics-opium derivatives | 185 |
Any of the following opium derivatives, including their | 186 |
salts, isomers, and salts of isomers, unless specifically excepted | 187 |
under federal drug abuse control laws, whenever the existence of | 188 |
these salts, isomers, and salts of isomers is possible within the | 189 |
specific chemical designation: | 190 |
(1) Acetorphine; | 191 |
(2) Acetyldihydrocodeine; | 192 |
(3) Benzylmorphine; | 193 |
(4) Codeine methylbromide; | 194 |
(5) Codeine-n-oxide; | 195 |
(6) Cyprenorphine; | 196 |
(7) Desomorphine; | 197 |
(8) Dihydromorphine; | 198 |
(9) Drotebanol; | 199 |
(10) Etorphine (except hydrochloride salt); | 200 |
(11) Heroin; | 201 |
(12) Hydromorphinol; | 202 |
(13) Methyldesorphine; | 203 |
(14) Methyldihydromorphine; | 204 |
(15) Morphine methylbromide; | 205 |
(16) Morphine methylsulfonate; | 206 |
(17) Morphine-n-oxide; | 207 |
(18) Myrophine; | 208 |
(19) Nicocodeine; | 209 |
(20) Nicomorphine; | 210 |
(21) Normorphine; | 211 |
(22) Pholcodine; | 212 |
(23) Thebacon. | 213 |
(C) Hallucinogens | 214 |
Any material, compound, mixture, or preparation that contains | 215 |
any quantity of the following hallucinogenic substances, including | 216 |
their salts, isomers, and salts of isomers, unless specifically | 217 |
excepted under federal drug abuse control laws, whenever the | 218 |
existence of these salts, isomers, and salts of isomers is | 219 |
possible within the specific chemical designation. For the | 220 |
purposes of this division only, "isomer" includes the optical | 221 |
isomers, position isomers, and geometric isomers. | 222 |
(1) Alpha-ethyltryptamine (some trade or other names: | 223 |
etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; | 224 |
3-(2-aminobutyl) indole; alpha-ET; and AET); | 225 |
(2) 4-bromo-2,5-dimethoxyamphetamine (some trade or other | 226 |
names: 4-bromo-2,5-dimethoxy-alpha-methyphenethylamine; | 227 |
4-bromo-2,5-DMA); | 228 |
(3) 4-bromo-2,5-dimethoxyphenethylamine (some trade or other | 229 |
names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; | 230 |
alpha-desmethyl DOB; 2C-B, Nexus); | 231 |
(4) 2,5-dimethoxyamphetamine (some trade or other names: | 232 |
2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 233 |
(5) 2,5-dimethoxy-4-ethylamphetamine (some trade or other | 234 |
names: DOET); | 235 |
(6) 4-methoxyamphetamine (some trade or other names: | 236 |
4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; | 237 |
PMA); | 238 |
(7) 5-methoxy-3,4-methylenedioxy-amphetamine; | 239 |
(8) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other | 240 |
names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM" | 241 |
and "STP"); | 242 |
(9) 3,4-methylenedioxy amphetamine (MDA); | 243 |
(10) 3,4-methylenedioxymethamphetamine (MDMA); | 244 |
(11) 3,4-methylenedioxy-N-ethylamphetamine (also known as | 245 |
N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl | 246 |
MDA, MDE, MDEA); | 247 |
(12) N-hydroxy-3,4-methylenedioxyamphetamine (also known as | 248 |
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine and | 249 |
N-hydroxy MDA); | 250 |
(13) 3,4,5-trimethoxy amphetamine; | 251 |
(14) Bufotenine (some trade or other names: | 252 |
3-(beta-dimethylaminoethyl)-5-hydroxyindole; | 253 |
3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; | 254 |
5-hydroxy-N, N-dimethyltryptamine; mappine); | 255 |
(15) Diethyltryptamine (some trade or other names: N, | 256 |
N-diethyltryptamine; DET); | 257 |
(16) Dimethyltryptamine (some trade or other names: DMT); | 258 |
(17) Ibogaine (some trade or other names: | 259 |
7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano- | 260 |
5H-pyrido[1',2':1,2] azepino [5, 4-b] indole; tabernanthe iboga); | 261 |
(18) Lysergic acid diethylamide; | 262 |
(19) Marihuana; | 263 |
(20) Mescaline; | 264 |
(21) Parahexyl (some trade or other names: 3-hexyl-1- | 265 |
hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; | 266 |
synhexyl); | 267 |
(22) Peyote (meaning all parts of the plant presently | 268 |
classified botanically as "Lophophora williamsii Lemaire," whether | 269 |
growing or not, the seeds of that plant, any extract from any part | 270 |
of that plant, and every compound, manufacture, salts, derivative, | 271 |
mixture, or preparation of that plant, its seeds, or its | 272 |
extracts); | 273 |
(23) N-ethyl-3-piperidyl benzilate; | 274 |
(24) N-methyl-3-piperidyl benzilate; | 275 |
(25) Psilocybin; | 276 |
(26) Psilocyn; | 277 |
(27) Tetrahydrocannabinols (synthetic equivalents of the | 278 |
substances contained in the plant, or in the resinous extractives | 279 |
of Cannabis, sp. and/or synthetic substances, derivatives, and | 280 |
their isomers with similar chemical structure and pharmacological | 281 |
activity such as the following: delta-1-cis or trans | 282 |
tetrahydrocannabinol, and their optical isomers; delta-6-cis or | 283 |
trans tetrahydrocannabinol, and their optical isomers; | 284 |
delta-3,4-cis or trans tetrahydrocannabinol, and its optical | 285 |
isomers. (Since nomenclature of these substances is not | 286 |
internationally standardized, compounds of these structures, | 287 |
regardless of numerical designation of atomic positions, are | 288 |
covered.)); | 289 |
(28) Ethylamine analog of phencyclidine (some trade or other | 290 |
names: N-ethyl-1-phenylcyclohexylamine; | 291 |
(1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; | 292 |
cyclohexamine; PCE); | 293 |
(29) Pyrrolidine analog of phencyclidine (some trade or other | 294 |
names: 1-(1-phenylcyclohexyl)pyrrolidine; PCPy; PHP); | 295 |
(30) Thiophene analog of phencyclidine (some trade or other | 296 |
names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog | 297 |
of phencyclidine; TPCP; TCP); | 298 |
(31) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; | 299 |
(32) Hashish; | 300 |
(33) Salvia divinorum; | 301 |
(34) Salvinorin A; | 302 |
(35) | 303 |
(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone | 304 |
(UR-144); | 305 |
(36) 1-pentyl-3-(1-adamantoyl)indole (AB-001); | 306 |
(37) N-adamantyl-1-pentylindole-3-carboxamide; | 307 |
(38) N-adamantyl-1-pentylindazole-3-carboxamide (AKB48); | 308 |
(39) 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone | 309 |
(methoxetamine); | 310 |
(40) N,N-diallyl-5-methoxytryptamine (5MeO-DALT); | 311 |
(41) | 312 |
[1-(5-fluoropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone | 313 |
(5-fluoropentyl-UR-144; XLR11); | 314 |
(42) | 315 |
[1-(5-chloropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone | 316 |
(5-chloropentyl-UR-144); | 317 |
(43) | 318 |
[1-(5-bromopentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone | 319 |
(5-bromopentyl-UR-144); | 320 |
(44) | 321 |
{1-[2-(4-morpholinyl)ethyl]indol-3-yl}-(2,2,3,3-tetramethylcyclopropyl) | 322 |
methanone (A-796,260); | 323 |
(45) | 324 |
1-[(N-methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole | 325 |
(AM1248); | 326 |
(46) N-adamantyl-1-(5-fluoropentylindole)-3-carboxamide; | 327 |
(47) 5-(2-aminopropyl)benzofuran (5-APB); | 328 |
(48) 6-(2-aminopropyl)benzofuran (6-APB); | 329 |
(49) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB); | 330 |
(50) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB); | 331 |
(51) Benzothiophenylcyclohexylpiperidine (BTCP); | 332 |
(52) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); | 333 |
(53) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); | 334 |
(54) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); | 335 |
(55) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); | 336 |
(56) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine | 337 |
(2C-T-2); | 338 |
(57) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine | 339 |
(2C-T-4); | 340 |
(58) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); | 341 |
(59) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); | 342 |
(60) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); | 343 |
(61) 4-methoxymethamphetamine (PMMA); | 344 |
(62) 5,6 - Methylenedioxy-2-aminoindane (MDAI); | 345 |
(63) 5-iodo-2-aminoindiane (5-IAI); | 346 |
(64) 2-(4-iodo-2,5-dimethoxyphenyl)-N- | 347 |
[(2-methoxyphenyl)methyl]ethanamine(25I-NBOMe); | 348 |
(65) Diphenylprolinol (diphenyl(pyrrolidin-2-yl)methanol, | 349 |
D2PM); | 350 |
(66) Desoxypipradrol (2-benzhydrylpiperidine); | 351 |
(67) Synthetic cannabinoids - unless specifically excepted or | 352 |
unless listed in another schedule, any material, compound, | 353 |
mixture, or preparation that contains any quantity of a synthetic | 354 |
cannabinoid found to be in any of the following chemical groups or | 355 |
any of those groups which contain any synthetic cannabinoid salts, | 356 |
isomers, or salts of isomers, whenever the existence of such | 357 |
salts, isomers, or salts of isomers is possible within the | 358 |
specific chemical groups: | 359 |
(a) Naphthoylindoles: any compound containing a | 360 |
3-(1-naphthoyl)indole structure with or without substitution at | 361 |
the nitrogen atom of the indole ring by an alkyl, haloalkyl, | 362 |
alkenyl, cycloalkylmethyl, cycloalkylethyl, | 363 |
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 364 |
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 365 |
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 366 |
whether or not further substituted on the indole ring to any | 367 |
extent or whether or not substituted on the naphthyl group to any | 368 |
extent. Naphthoylindoles include, but are not limited to, | 369 |
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); | 370 |
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), | 371 |
1-pentyl-3-(1-naphthoyl)indole (JWH-018), and | 372 |
1-butyl-3-(1-naphthoyl)indole (JWH-073). | 373 |
(b) Naphthylmethylindoles: any compound containing a | 374 |
1H-indol-3-yl-(1-naphthyl)methane structure with or without | 375 |
substitution at the nitrogen atom of the indole ring by an alkyl, | 376 |
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 377 |
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 378 |
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 379 |
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 380 |
whether or not further substituted on the indole ring to any | 381 |
extent or whether or not substituted on the naphthyl group to any | 382 |
extent. Naphthylmethylindoles include, but are not limited to, | 383 |
(1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175). | 384 |
(c) Naphthoylpyrroles: any compound containing a | 385 |
3-(1-naphthoyl)pyrrole structure with or without substitution at | 386 |
the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, | 387 |
alkenyl, cycloalkylmethyl, cycloalkylethyl, | 388 |
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 389 |
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 390 |
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 391 |
whether or not further substituted on the pyrrole ring to any | 392 |
extent or whether or not substituted on the naphthyl group to any | 393 |
extent. Naphthoylpyrroles include, but are not limited to, | 394 |
1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147). | 395 |
(d) Naphthylmethylindenes: any compound containing a | 396 |
naphthylmethylideneindene structure with or without substitution | 397 |
at the 3-position of the indene ring by an alkyl, haloalkyl, | 398 |
alkenyl, cycloalkylmethyl, cycloalkylethyl, | 399 |
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 400 |
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 401 |
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 402 |
whether or not further substituted on the indene group to any | 403 |
extent or whether or not substituted on the naphthyl group to any | 404 |
extent. Naphthylmethylindenes include, but are not limited to, | 405 |
(1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176). | 406 |
(e) Phenylacetylindoles: any compound containing a | 407 |
3-phenylacetylindole structure with or without substitution at the | 408 |
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, | 409 |
cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, | 410 |
cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | 411 |
(tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl, or | 412 |
2-(4-morpholinyl)ethyl group, whether or not further substituted | 413 |
on the indole ring to any extent or whether or not substituted on | 414 |
the phenyl group to any extent. Phenylacetylindoles include, but | 415 |
are not limited to, 1-pentyl-3-(2-methoxyphenylacetyl)indole | 416 |
(JWH-250), and | 417 |
1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8); | 418 |
1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203). | 419 |
(f) Cyclohexylphenols: any compound containing a | 420 |
2-(3-hydroxycyclohexyl)phenol structure with or without | 421 |
substitution at the 5-position of the phenolic ring by an alkyl, | 422 |
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, | 423 |
(N-methylpiperidin-2-yl)methyl, cyanoalkyl, | 424 |
(N-methylpyrrolidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, | 425 |
((N-methyl)-3-morpholinyl)methyl, or 2-(4-morpholinyl)ethyl group, | 426 |
whether or not further substituted on the cyclohexyl group to any | 427 |
extent. Cyclohexylphenols include, but are not limited to, | 428 |
5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | 429 |
(some trade or other names: CP-47,497) and | 430 |
5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (some | 431 |
trade or other names: cannabicyclohexanol; CP-47,497 C8 | 432 |
homologue). | 433 |
(g) Benzoylindoles: any compound containing a 3-( | 434 |
1-benzoyl)indole structure with or without substitution at the | 435 |
nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, | 436 |
cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, | 437 |
cyanoalkyl, (N-methylpyrrolidin-2-yl)methyl, | 438 |
(tetrahydropyran-4-yl)methyl, ((N-methyl)-3-morpholinyl)methyl or | 439 |
2-(4-morpholinyl)ethyl group, whether or not further substituted | 440 |
on the indole ring to any extent or whether or not substituted on | 441 |
the phenyl group to any extent. Benzoylindoles include, but are | 442 |
not limited to, 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4), | 443 |
1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoyl)indole | 444 |
(Pravadoline or WIN 48, 098). | 445 |
(D) Depressants | 446 |
Any material, compound, mixture, or preparation that contains | 447 |
any quantity of the following substances having a depressant | 448 |
effect on the central nervous system, including their salts, | 449 |
isomers, and salts of isomers, unless specifically excepted under | 450 |
federal drug abuse control laws, whenever the existence of these | 451 |
salts, isomers, and salts of isomers is possible within the | 452 |
specific chemical designation: | 453 |
(1) Mecloqualone; | 454 |
(2) Methaqualone. | 455 |
(E) Stimulants | 456 |
Unless specifically excepted or unless listed in another | 457 |
schedule, any material, compound, mixture, or preparation that | 458 |
contains any quantity of the following substances having a | 459 |
stimulant effect on the central nervous system, including their | 460 |
salts, isomers, and salts of isomers: | 461 |
(1) Aminorex (some other names: aminoxaphen; | 462 |
2-amino-5-phenyl-2-oxazoline; or | 463 |
4,5-dihydro-5-phenyl-2-oxazolamine); | 464 |
(2) Fenethylline; | 465 |
(3) (+/-)cis-4-methylaminorex | 466 |
((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine); | 467 |
(4) N-ethylamphetamine; | 468 |
(5) N,N-dimethylamphetamine (also known as | 469 |
N,N-alpha-trimethyl-benzeneethanamine; | 470 |
N,N-alpha-trimethylphenethylamine); | 471 |
(6) N-methyl-1-(thiophen-2-yl) propan-2-amine | 472 |
(Methiopropamine); | 473 |
(7) Substituted cathinones - any compound except bupropion or | 474 |
compounds listed under a different schedule, structurally derived | 475 |
from 2-aminopropan-1-one by substitution at the 1-position with | 476 |
either phenyl, naphthyl, or thiophene ring systems, whether or not | 477 |
the compound is further modified in any of the following ways: | 478 |
(a) By substitution in the ring system to any extent with | 479 |
alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide | 480 |
substituents, whether or not further substituted in the ring | 481 |
system by one or more other univalent substituents; | 482 |
(b) By substitution at the 3-position with an acyclic alkyl | 483 |
substituent; | 484 |
(c) By substitution at the 2-amino nitrogen atom with alkyl, | 485 |
dialkyl, benzyl, or methoxybenzyl groups; | 486 |
(d) By inclusion of the 2-amino nitrogen atom in a cyclic | 487 |
structure. | 488 |
Examples of substituted cathinones include, but are not | 489 |
limited to, methylone (3,4-methylenedioxymethcathinone), MDPV | 490 |
(3,4-methylenedioxypyrovalerone), mephedrone | 491 |
(4-methylmethcathinone), 4-methoxymethcathinone, | 492 |
4-fluoromethcathinone, 3-fluoromethcathinone, Pentedrone | 493 |
(2-(methylamino)-1-phenyl-1-pentanone), pentylone | 494 |
(1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-pentanone), | 495 |
2-(1-pyrrolidinyl)-1-(4-methylphenyl)-1-propanone, alpha-PVP | 496 |
(1-phenyl-2-(1-pyrrodinyl)-1-pentanone), cathinone | 497 |
(2-amino-1-phenyl-1-propanone), and methcathinone | 498 |
(2-(methylamino)-propiophenone). | 499 |
500 | |
(A) Narcotics-opium and opium derivatives | 501 |
Unless specifically excepted under federal drug abuse control | 502 |
laws or unless listed in another schedule, any of the following | 503 |
substances whether produced directly or indirectly by extraction | 504 |
from substances of vegetable origin, independently by means of | 505 |
chemical synthesis, or by a combination of extraction and chemical | 506 |
synthesis: | 507 |
(1) Opium and opiate, and any salt, compound, derivative, or | 508 |
preparation of opium or opiate, excluding apomorphine, | 509 |
thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, | 510 |
naloxone, and naltrexone, and their respective salts, but | 511 |
including the following: | 512 |
(a) Raw opium; | 513 |
(b) Opium extracts; | 514 |
(c) Opium fluid extracts; | 515 |
(d) Powdered opium; | 516 |
(e) Granulated opium; | 517 |
(f) Tincture of opium; | 518 |
(g) Codeine; | 519 |
(h) Ethylmorphine; | 520 |
(i) Etorphine hydrochloride; | 521 |
(j) Hydrocodone; | 522 |
(k) Hydromorphone; | 523 |
(l) Metopon; | 524 |
(m) Morphine; | 525 |
(n) Oxycodone; | 526 |
(o) Oxymorphone; | 527 |
(p) Thebaine. | 528 |
(2) Any salt, compound, derivative, or preparation thereof | 529 |
that is chemically equivalent to or identical with any of the | 530 |
substances referred to in division (A)(1) of this schedule, except | 531 |
that these substances shall not include the isoquinoline alkaloids | 532 |
of opium; | 533 |
(3) Opium poppy and poppy straw; | 534 |
(4) Coca leaves and any salt, compound, derivative, or | 535 |
preparation of coca leaves (including cocaine and ecgonine, their | 536 |
salts, isomers, and derivatives, and salts of those isomers and | 537 |
derivatives), and any salt, compound, derivative, or preparation | 538 |
thereof that is chemically equivalent to or identical with any of | 539 |
these substances, except that the substances shall not include | 540 |
decocainized coca leaves or extraction of coca leaves, which | 541 |
extractions do not contain cocaine or ecgonine; | 542 |
(5) Concentrate of poppy straw (the crude extract of poppy | 543 |
straw in either liquid, solid, or powder form that contains the | 544 |
phenanthrene alkaloids of the opium poppy). | 545 |
(B) Narcotics-opiates | 546 |
Unless specifically excepted under federal drug abuse control | 547 |
laws or unless listed in another schedule, any of the following | 548 |
opiates, including their isomers, esters, ethers, salts, and salts | 549 |
of isomers, esters, and ethers, whenever the existence of these | 550 |
isomers, esters, ethers, and salts is possible within the specific | 551 |
chemical designation, but excluding dextrorphan and | 552 |
levopropoxyphene: | 553 |
(1) Alfentanil; | 554 |
(2) Alphaprodine; | 555 |
(3) Anileridine; | 556 |
(4) Bezitramide; | 557 |
(5) Bulk dextropropoxyphene (non-dosage forms); | 558 |
(6) Carfentanil; | 559 |
(7) Dihydrocodeine; | 560 |
(8) Diphenoxylate; | 561 |
(9) Fentanyl; | 562 |
(10) Isomethadone; | 563 |
(11) Levo-alphacetylmethadol (some other names: | 564 |
levo-alpha-acetylmethadol; levomethadyl acetate; LAAM); | 565 |
(12) Levomethorphan; | 566 |
(13) Levorphanol; | 567 |
(14) Metazocine; | 568 |
(15) Methadone; | 569 |
(16) Methadone-intermediate, | 570 |
4-cyano-2-dimethylamino-4,4-diphenyl butane; | 571 |
(17) Moramide-intermediate, | 572 |
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid; | 573 |
(18) Pethidine (meperidine); | 574 |
(19) Pethidine-intermediate-A, | 575 |
4-cyano-1-methyl-4-phenylpiperidine; | 576 |
(20) Pethidine-intermediate-B, | 577 |
ethyl-4-phenylpiperidine-4-carboxylate; | 578 |
(21) Pethidine-intermediate-C, | 579 |
1-methyl-4-phenylpiperidine-4-carboxylic acid; | 580 |
(22) Phenazocine; | 581 |
(23) Piminodine; | 582 |
(24) Racemethorphan; | 583 |
(25) Racemorphan; | 584 |
(26) Remifentanil; | 585 |
(27) Sufentanil. | 586 |
(C) Stimulants | 587 |
Unless specifically excepted under federal drug abuse control | 588 |
laws or unless listed in another schedule, any material, compound, | 589 |
mixture, or preparation that contains any quantity of the | 590 |
following substances having a stimulant effect on the central | 591 |
nervous system: | 592 |
(1) Amphetamine, its salts, its optical isomers, and salts of | 593 |
its optical isomers; | 594 |
(2) Methamphetamine, its salts, its isomers, and salts of its | 595 |
isomers; | 596 |
(3) Methylphenidate; | 597 |
(4) Phenmetrazine and its salts. | 598 |
(D) Depressants | 599 |
Unless specifically excepted under federal drug abuse control | 600 |
laws or unless listed in another schedule, any material, compound, | 601 |
mixture, or preparation that contains any quantity of the | 602 |
following substances having a depressant effect on the central | 603 |
nervous system, including their salts, isomers, and salts of | 604 |
isomers, whenever the existence of these salts, isomers, and salts | 605 |
of isomers is possible within the specific chemical designation: | 606 |
(1) Amobarbital; | 607 |
(2) Gamma-hydroxy-butyrate; | 608 |
(3) Glutethimide; | 609 |
(4) Pentobarbital; | 610 |
(5) Phencyclidine (some trade or other names: | 611 |
1-(1-phenylcyclohexyl)piperidine; PCP); | 612 |
(6) Secobarbital; | 613 |
(7) 1-aminophenylcyclohexane and all N-mono-substituted | 614 |
and/or all N-N-disubstituted analogs including, but not limited | 615 |
to, the following: | 616 |
(a) 1-phenylcyclohexylamine; | 617 |
(b) (1-phenylcyclohexyl) methylamine; | 618 |
(c) (1-phenylcyclohexyl) dimethylamine; | 619 |
(d) (1-phenylcyclohexyl) methylethylamine; | 620 |
(e) (1-phenylcyclohexyl) isopropylamine; | 621 |
(f) 1-(1-phenylcyclohexyl) morpholine. | 622 |
(E) Hallucinogenic substances | 623 |
(1) Nabilone (another name for nabilone: | 624 |
(+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1- | 625 |
hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one). | 626 |
(F) Immediate precursors | 627 |
Unless specifically excepted under federal drug abuse control | 628 |
laws or unless listed in another schedule, any material, compound, | 629 |
mixture, or preparation that contains any quantity of the | 630 |
following substances: | 631 |
(1) Immediate precursor to amphetamine and methamphetamine: | 632 |
(a) Phenylacetone (some trade or other names: | 633 |
phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl | 634 |
ketone); | 635 |
(2) Immediate precursors to phencyclidine (PCP): | 636 |
(a) 1-phenylcyclohexylamine; | 637 |
(b) 1-piperidinocyclohexanecarbonitrile (PCC). | 638 |
639 | |
(A) Stimulants | 640 |
Unless specifically excepted under federal drug abuse control | 641 |
laws or unless listed in another schedule, any material, compound, | 642 |
mixture, or preparation that contains any quantity of the | 643 |
following substances having a stimulant effect on the central | 644 |
nervous system, including their salts, their optical isomers, | 645 |
position isomers, or geometric isomers, and salts of these | 646 |
isomers, whenever the existence of these salts, isomers, and salts | 647 |
of isomers is possible within the specific chemical designation: | 648 |
(1) All stimulant compounds, mixtures, and preparations | 649 |
included in schedule III pursuant to the federal drug abuse | 650 |
control laws and regulations adopted under those laws; | 651 |
(2) Benzphetamine; | 652 |
(3) Chlorphentermine; | 653 |
(4) Clortermine; | 654 |
(5) Phendimetrazine. | 655 |
(B) Depressants | 656 |
Unless specifically excepted under federal drug abuse control | 657 |
laws or unless listed in another schedule, any material, compound, | 658 |
mixture, or preparation that contains any quantity of the | 659 |
following substances having a depressant effect on the central | 660 |
nervous system: | 661 |
(1) Any compound, mixture, or preparation containing | 662 |
amobarbital, secobarbital, pentobarbital, or any salt of any of | 663 |
these drugs, and one or more other active medicinal ingredients | 664 |
that are not listed in any schedule; | 665 |
(2) Any suppository dosage form containing amobarbital, | 666 |
secobarbital, pentobarbital, or any salt of any of these drugs and | 667 |
approved by the food and drug administration for marketing only as | 668 |
a suppository; | 669 |
(3) Any substance that contains any quantity of a derivative | 670 |
of barbituric acid or any salt of a derivative of barbituric acid; | 671 |
(4) Chlorhexadol; | 672 |
(5) Ketamine, its salts, isomers, and salts of isomers (some | 673 |
other names for ketamine: | 674 |
(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone); | 675 |
(6) Lysergic acid; | 676 |
(7) Lysergic acid amide; | 677 |
(8) Methyprylon; | 678 |
(9) Sulfondiethylmethane; | 679 |
(10) Sulfonethylmethane; | 680 |
(11) Sulfonmethane; | 681 |
(12) Tiletamine, zolazepam, or any salt of tiletamine or | 682 |
zolazepam (some trade or other names for a tiletamine-zolazepam | 683 |
combination product: Telazol); (some trade or other names for | 684 |
tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some | 685 |
trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8- | 686 |
dihydro-1,3,8-trimethylpyrazolo-[3, 4-e][1,4]-diazepin-7(1H)-one; | 687 |
flupyrazapon). | 688 |
(C) Narcotic antidotes | 689 |
(1) Nalorphine. | 690 |
(D) Narcotics-narcotic preparations | 691 |
Unless specifically excepted under federal drug abuse control | 692 |
laws or unless listed in another schedule, any material, compound, | 693 |
mixture, or preparation that contains any of the following | 694 |
narcotic drugs, or their salts calculated as the free anhydrous | 695 |
base or alkaloid, in limited quantities as set forth below: | 696 |
(1) Not more than 1.8 grams of codeine per 100 milliliters or | 697 |
not more than 90 milligrams per dosage unit, with an equal or | 698 |
greater quantity of an isoquinoline alkaloid of opium; | 699 |
(2) Not more than 1.8 grams of codeine per 100 milliliters or | 700 |
not more than 90 milligrams per dosage unit, with one or more | 701 |
active, nonnarcotic ingredients in recognized therapeutic amounts; | 702 |
(3) Not more than 300 milligrams of dihydrocodeinone per 100 | 703 |
milliliters or not more than 15 milligrams per dosage unit, with a | 704 |
fourfold or greater quantity of an isoquinoline alkaloid of opium; | 705 |
(4) Not more than 300 milligrams of dihydrocodeinone per 100 | 706 |
milliliters or not more than 15 milligrams per dosage unit, with | 707 |
one or more active, nonnarcotic ingredients in recognized | 708 |
therapeutic amounts; | 709 |
(5) Not more than 1.8 grams of dihydrocodeine per 100 | 710 |
milliliters or not more than 90 milligrams per dosage unit, with | 711 |
one or more active, nonnarcotic ingredients in recognized | 712 |
therapeutic amounts; | 713 |
(6) Not more than 300 milligrams of ethylmorphine per 100 | 714 |
milliliters or not more than 15 milligrams per dosage unit, with | 715 |
one or more active, nonnarcotic ingredients in recognized | 716 |
therapeutic amounts; | 717 |
(7) Not more than 500 milligrams of opium per 100 milliliters | 718 |
or per 100 grams or not more than 25 milligrams per dosage unit, | 719 |
with one or more active, nonnarcotic ingredients in recognized | 720 |
therapeutic amounts; | 721 |
(8) Not more than 50 milligrams of morphine per 100 | 722 |
milliliters or per 100 grams, with one or more active, nonnarcotic | 723 |
ingredients in recognized therapeutic amounts. | 724 |
(E) Anabolic steroids | 725 |
Unless specifically excepted under federal drug abuse control | 726 |
laws or unless listed in another schedule, any material, compound, | 727 |
mixture, or preparation that contains any quantity of the | 728 |
following substances, including their salts, esters, isomers, and | 729 |
salts of esters and isomers, whenever the existence of these | 730 |
salts, esters, and isomers is possible within the specific | 731 |
chemical designation: | 732 |
(1) Anabolic steroids. Except as otherwise provided in | 733 |
division (E)(1) of schedule III, "anabolic steroids" means any | 734 |
drug or hormonal substance that is chemically and | 735 |
pharmacologically related to testosterone (other than estrogens, | 736 |
progestins, and corticosteroids) and that promotes muscle growth. | 737 |
"Anabolic steroids" does not include an anabolic steroid that is | 738 |
expressly intended for administration through implants to cattle | 739 |
or other nonhuman species and that has been approved by the United | 740 |
States secretary of health and human services for that | 741 |
administration, unless a person prescribes, dispenses, or | 742 |
distributes this type of anabolic steroid for human use. "Anabolic | 743 |
steroid" includes, but is not limited to, the following: | 744 |
(a) Boldenone; | 745 |
(b) Chlorotestosterone (4-chlortestosterone); | 746 |
(c) Clostebol; | 747 |
(d) Dehydrochlormethyltestosterone; | 748 |
(e) Dihydrotestosterone (4-dihydrotestosterone); | 749 |
(f) Drostanolone; | 750 |
(g) Ethylestrenol; | 751 |
(h) Fluoxymesterone; | 752 |
(i) Formebulone (formebolone); | 753 |
(j) Mesterolone; | 754 |
(k) Methandienone; | 755 |
(l) Methandranone; | 756 |
(m) Methandriol; | 757 |
(n) Methandrostenolone; | 758 |
(o) Methenolone; | 759 |
(p) Methyltestosterone; | 760 |
(q) Mibolerone; | 761 |
(r) Nandrolone; | 762 |
(s) Norethandrolone; | 763 |
(t) Oxandrolone; | 764 |
(u) Oxymesterone; | 765 |
(v) Oxymetholone; | 766 |
(w) Stanolone; | 767 |
(x) Stanozolol; | 768 |
(y) Testolactone; | 769 |
(z) Testosterone; | 770 |
(aa) Trenbolone; | 771 |
(bb) Any salt, ester, isomer, or salt of an ester or isomer | 772 |
of a drug or hormonal substance described or listed in division | 773 |
(E)(1) of schedule III if the salt, ester, or isomer promotes | 774 |
muscle growth. | 775 |
(F) Hallucinogenic substances | 776 |
(1) Dronabinol (synthetic) in sesame oil and encapsulated in | 777 |
a soft gelatin capsule in a United States food and drug | 778 |
administration approved drug product (some other names for | 779 |
dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- | 780 |
6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or | 781 |
(-)-delta-9-(trans)-tetrahydrocannabinol). | 782 |
783 | |
(A) Narcotic drugs | 784 |
Unless specifically excepted by federal drug abuse control | 785 |
laws or unless listed in another schedule, any material, compound, | 786 |
mixture, or preparation that contains any of the following | 787 |
narcotic drugs, or their salts calculated as the free anhydrous | 788 |
base or alkaloid, in limited quantities as set forth below: | 789 |
(1) Not more than one milligram of difenoxin and not less | 790 |
than 25 micrograms of atropine sulfate per dosage unit; | 791 |
(2) Dextropropoxyphene | 792 |
(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- | 793 |
propionoxybutane)[final dosage forms]. | 794 |
(B) Depressants | 795 |
Unless specifically excepted under federal drug abuse control | 796 |
laws or unless listed in another schedule, any material, compound, | 797 |
mixture, or preparation that contains any quantity of the | 798 |
following substances, including their salts, isomers, and salts of | 799 |
isomers, whenever the existence of these salts, isomers, and salts | 800 |
of isomers is possible within the specific chemical designation: | 801 |
(1) Alprazolam; | 802 |
(2) Barbital; | 803 |
(3) Bromazepam; | 804 |
(4) Camazepam; | 805 |
(5) Chloral betaine; | 806 |
(6) Chloral hydrate; | 807 |
(7) Chlordiazepoxide; | 808 |
(8) Clobazam; | 809 |
(9) Clonazepam; | 810 |
(10) Clorazepate; | 811 |
(11) Clotiazepam; | 812 |
(12) Cloxazolam; | 813 |
(13) Delorazepam; | 814 |
(14) Diazepam; | 815 |
(15) Estazolam; | 816 |
(16) Ethchlorvynol; | 817 |
(17) Ethinamate; | 818 |
(18) Ethyl loflazepate; | 819 |
(19) Fludiazepam; | 820 |
(20) Flunitrazepam; | 821 |
(21) Flurazepam; | 822 |
(22) Halazepam; | 823 |
(23) Haloxazolam; | 824 |
(24) Ketazolam; | 825 |
(25) Loprazolam; | 826 |
(26) Lorazepam; | 827 |
(27) Lormetazepam; | 828 |
(28) Mebutamate; | 829 |
(29) Medazepam; | 830 |
(30) Meprobamate; | 831 |
(31) Methohexital; | 832 |
(32) Methylphenobarbital (mephobarbital); | 833 |
(33) Midazolam; | 834 |
(34) Nimetazepam; | 835 |
(35) Nitrazepam; | 836 |
(36) Nordiazepam; | 837 |
(37) Oxazepam; | 838 |
(38) Oxazolam; | 839 |
(39) Paraldehyde; | 840 |
(40) Petrichloral; | 841 |
(41) Phenobarbital; | 842 |
(42) Pinazepam; | 843 |
(43) Prazepam; | 844 |
(44) Quazepam; | 845 |
(45) Temazepam; | 846 |
(46) Tetrazepam; | 847 |
(47) Triazolam; | 848 |
(48) Zaleplon; | 849 |
(49) Zolpidem. | 850 |
(C) Fenfluramine | 851 |
Any material, compound, mixture, or preparation that contains | 852 |
any quantity of the following substances, including their salts, | 853 |
their optical isomers, position isomers, or geometric isomers, and | 854 |
salts of these isomers, whenever the existence of these salts, | 855 |
isomers, and salts of isomers is possible within the specific | 856 |
chemical designation: | 857 |
(1) Fenfluramine. | 858 |
(D) Stimulants | 859 |
Unless specifically excepted under federal drug abuse control | 860 |
laws or unless listed in another schedule, any material, compound, | 861 |
mixture, or preparation that contains any quantity of the | 862 |
following substances having a stimulant effect on the central | 863 |
nervous system, including their salts, their optical isomers, | 864 |
position isomers, or geometric isomers, and salts of these | 865 |
isomers, whenever the existence of these salts, isomers, and salts | 866 |
of isomers is possible within the specific chemical designation: | 867 |
(1) Cathine ((+)-norpseudoephedrine); | 868 |
(2) Diethylpropion; | 869 |
(3) Fencamfamin; | 870 |
(4) Fenproporex; | 871 |
(5) Mazindol; | 872 |
(6) Mefenorex; | 873 |
(7) Modafinil; | 874 |
(8) Pemoline (including organometallic complexes and chelates | 875 |
thereof); | 876 |
(9) Phentermine; | 877 |
(10) Pipradrol; | 878 |
(11) Sibutramine; | 879 |
(12) SPA [(-)-1-dimethylamino-1,2-diphenylethane]. | 880 |
(E) Other substances | 881 |
Unless specifically excepted under federal drug abuse control | 882 |
laws or unless listed in another schedule, any material, compound, | 883 |
mixture, or preparation that contains any quantity of the | 884 |
following substances, including their salts: | 885 |
(1) Pentazocine; | 886 |
(2) Butorphanol (including its optical isomers). | 887 |
888 | |
(A) Narcotic drugs | 889 |
Unless specifically excepted under federal drug abuse control | 890 |
laws or unless listed in another schedule, any material, compound, | 891 |
mixture, or preparation that contains any of the following | 892 |
narcotic drugs, and their salts, as set forth below: | 893 |
(1) Buprenorphine. | 894 |
(B) Narcotics-narcotic preparations | 895 |
Narcotic drugs containing non-narcotic active medicinal | 896 |
ingredients. Any compound, mixture, or preparation that contains | 897 |
any of the following narcotic drugs, or their salts calculated as | 898 |
the free anhydrous base or alkaloid, in limited quantities as set | 899 |
forth below, and that includes one or more nonnarcotic active | 900 |
medicinal ingredients in sufficient proportion to confer upon the | 901 |
compound, mixture, or preparation valuable medicinal qualities | 902 |
other than those possessed by narcotic drugs alone: | 903 |
(1) Not more than 200 milligrams of codeine per 100 | 904 |
milliliters or per 100 grams; | 905 |
(2) Not more than 100 milligrams of dihydrocodeine per 100 | 906 |
milliliters or per 100 grams; | 907 |
(3) Not more than 100 milligrams of ethylmorphine per 100 | 908 |
milliliters or per 100 grams; | 909 |
(4) Not more than 2.5 milligrams of diphenoxylate and not | 910 |
less than 25 micrograms of atropine sulfate per dosage unit; | 911 |
(5) Not more than 100 milligrams of opium per 100 milliliters | 912 |
or per 100 grams; | 913 |
(6) Not more than 0.5 milligram of difenoxin and not less | 914 |
than 25 micrograms of atropine sulfate per dosage unit. | 915 |
(C) Stimulants | 916 |
Unless specifically exempted or excluded under federal drug | 917 |
abuse control laws or unless listed in another schedule, any | 918 |
material, compound, mixture, or preparation that contains any | 919 |
quantity of the following substances having a stimulant effect on | 920 |
the central nervous system, including their salts, isomers, and | 921 |
salts of isomers: | 922 |
(1) Ephedrine, except as provided in division (K) of section | 923 |
3719.44 of the Revised Code; | 924 |
(2) Pyrovalerone. | 925 |
Section 2. That existing sections 3711.12 and 3719.41 of the | 926 |
Revised Code are hereby repealed. | 927 |